Medications

India revokes cancer drug patent in fresh industry blow

India has revoked a local patent granted to Britain's GlaxoSmithKline for a breast cancer drug in the latest blow to global companies seeking a bigger presence in the country's $13 billion medicine market.

Oncology & Cancer

Study predicts cancer drug responsiveness in human tumors

It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex environment of the body.

Oncology & Cancer

Are too few women being offered breast-conserving treatment?

Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns ...

page 1 from 2

Lapatinib

Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. It is used in combination therapy for HER2-positive breast cancer. It has been approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.

This text uses material from Wikipedia, licensed under CC BY-SA